233 related articles for article (PubMed ID: 21389327)
21. CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells.
Barakat DJ; Zhang J; Barberi T; Denmeade SR; Friedman AD; Paz-Priel I
Oncogene; 2015 Nov; 34(48):5912-22. PubMed ID: 25772238
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of collagen gene expression by interferon-gamma: novel role of the CCAAT/enhancer binding protein beta (C/EBPbeta).
Ghosh AK; Bhattacharyya S; Mori Y; Varga J
J Cell Physiol; 2006 Apr; 207(1):251-60. PubMed ID: 16331681
[TBL] [Abstract][Full Text] [Related]
23. [Pomalidomide for multiple myeloma].
Dougé A; Lemal R; Chaleteix C
Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
[TBL] [Abstract][Full Text] [Related]
24. Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.
Kondo N; Nagano Y; Hasegawa A; Ishizawa M; Katagiri K; Yoneda T; Masuda T; Kannagi M
Biochem Biophys Res Commun; 2021 Oct; 574():104-109. PubMed ID: 34455369
[TBL] [Abstract][Full Text] [Related]
25. Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
Wu W; Nelson GM; Koch R; Donovan KA; Nowak RP; Heavican-Foral TB; Nirmal AJ; Liu H; Yang L; Duffy J; Powers F; Stevenson KE; Jones MK; Ng SY; Wu G; Jain S; Xu R; Amaka S; Trevisani C; Donaldson NL; Hagner PR; de Leval L; Gaulard P; Iqbal J; Thakurta A; Fischer ES; Adelman K; Weinstock DM
Blood; 2022 Mar; 139(13):2024-2037. PubMed ID: 34936696
[TBL] [Abstract][Full Text] [Related]
26. Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins (C/EBPs): decreased C/EBPbeta in endometriosis is associated with overexpression of aromatase.
Yang S; Fang Z; Suzuki T; Sasano H; Zhou J; Gurates B; Tamura M; Ferrer K; Bulun S
J Clin Endocrinol Metab; 2002 May; 87(5):2336-45. PubMed ID: 11994385
[TBL] [Abstract][Full Text] [Related]
27. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
[TBL] [Abstract][Full Text] [Related]
28. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
Zhu YX; Yin H; Bruins LA; Shi CX; Jedlowski P; Aziz M; Sereduk C; Kortuem KM; Schmidt JE; Champion M; Braggio E; Keith Stewart A
Blood; 2015 Jan; 125(3):483-91. PubMed ID: 25395420
[TBL] [Abstract][Full Text] [Related]
29. Role of IRF4 in resistance to immunomodulatory (IMid) compounds
Bertrand E; Jouy N; Manier S; Fouquet G; Guidez S; Boyle E; Noel S; Tomowiak C; Herbaux C; Schraen S; Preudhomme C; Quesnel B; Poulain S; Leleu X
Oncotarget; 2017 Dec; 8(68):112917-112927. PubMed ID: 29348877
[TBL] [Abstract][Full Text] [Related]
30. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
Henry JY; Labarthe MC; Meyer B; Dasgupta P; Dalgleish AG; Galustian C
Immunology; 2013 Jul; 139(3):377-85. PubMed ID: 23374145
[TBL] [Abstract][Full Text] [Related]
31. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
32. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Canella A; Cordero Nieves H; Sborov DW; Cascione L; Radomska HS; Smith E; Stiff A; Consiglio J; Caserta E; Rizzotto L; Zanesi N; Stefano V; Kaur B; Mo X; Byrd JC; Efebera YA; Hofmeister CC; Pichiorri F
Oncotarget; 2015 Oct; 6(31):31134-50. PubMed ID: 26429859
[TBL] [Abstract][Full Text] [Related]
33. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation.
Fan S; Li Y; Yue P; Khuri FR; Sun SY
Neoplasia; 2010 Apr; 12(4):346-56. PubMed ID: 20360945
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
Kuwahara-Ota S; Shimura Y; Steinebach C; Isa R; Yamaguchi J; Nishiyama D; Fujibayashi Y; Takimoto-Shimomura T; Mizuno Y; Matsumura-Kimoto Y; Tsukamoto T; Chinen Y; Kobayashi T; Horiike S; Taniwaki M; Gütschow M; Kuroda J
Br J Haematol; 2020 Dec; 191(5):784-795. PubMed ID: 32558939
[TBL] [Abstract][Full Text] [Related]
35. Reciprocal expression of CCAAT/enhancer binding proteins alpha and beta in hepatoblastomas and its prognostic significance.
Tomizawa M; Horie H; Yamamoto H; Matsunaga T; Sasaki F; Hashizume K; Hiyama E; Kaneko M; Suita S; Ando H; Hayashi Y; Ohnuma N; Nakagawara A
Oncol Rep; 2007 Feb; 17(2):341-4. PubMed ID: 17203171
[TBL] [Abstract][Full Text] [Related]
36. Multiple myeloma cells' capacity to decompose H
Sebastian S; Zhu YX; Braggio E; Shi CX; Panchabhai SC; Van Wier SA; Ahmann GJ; Chesi M; Bergsagel PL; Stewart AK; Fonseca R
Blood; 2017 Feb; 129(8):991-1007. PubMed ID: 28028022
[TBL] [Abstract][Full Text] [Related]
37. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
[TBL] [Abstract][Full Text] [Related]
38. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
Tang S; Ma D; Cheng B; Fang Q; Kuang X; Yu K; Wang W; Hu B; Wang J
Exp Cell Res; 2018 Feb; 363(2):196-207. PubMed ID: 29317217
[TBL] [Abstract][Full Text] [Related]
39. Col1a1 promoter-targeted expression of p20 CCAAT enhancer-binding protein beta (C/EBPbeta), a truncated C/EBPbeta isoform, causes osteopenia in transgenic mice.
Harrison JR; Huang YF; Wilson KA; Kelly PL; Adams DJ; Gronowicz GA; Clark SH
J Biol Chem; 2005 Mar; 280(9):8117-24. PubMed ID: 15598659
[TBL] [Abstract][Full Text] [Related]
40. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
